Teva will have exclusive marketing rights to
episil, an oncology supportive care product, in Germany, Spain, Poland,
Switzerland and the Czech Republic.
Teva Pharmaceutical Industries Ltd has teamed up with Britain's Sinclair IS Pharma plc to market Sinclair's oncology care product in five European countries, beginning in the fourth quarter.
Teva will have exclusive marketing rights to Episil, an oncology supportive care product, in Germany, Spain, Poland, Switzerland and the Czech Republic. Sinclair has an option to jointly market the product in Germany and Spain where it has its own direct sales force.
Episil is a patented oral spray for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.
Teva Pharmaceutical Industries Ltd has teamed up with Britain's Sinclair IS Pharma plc to market Sinclair's oncology care product in five European countries, beginning in the fourth quarter.
Teva will have exclusive marketing rights to Episil, an oncology supportive care product, in Germany, Spain, Poland, Switzerland and the Czech Republic. Sinclair has an option to jointly market the product in Germany and Spain where it has its own direct sales force.
Episil is a patented oral spray for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.
No comments:
Post a Comment